Get my own profile
Public access
View all21 articles
0 articles
available
not available
Based on funding mandates
Co-authors
- Ebba SohlbergPhD, Karolinska InstitutetVerified email at ki.se
- Eivind Heggernes AskUniversity of Oslo, Oslo University HospitalVerified email at uio.no
- Vincent, Yi Sheng OeiUniversity of Oslo / Duke-NUS Medical SchoolVerified email at u.duke.nus.edu
- Trevor ClancyCo-founder at NEC OncoImmunity. Professor at Nagasaki UniversityVerified email at oncoimmunity.com
- Quirin HammerTeam leader, Karolinska InstitutetVerified email at ki.se
- Björn ÖnfeltDepartment of Applied Physics, KTH Royal Institute of TechnologyVerified email at scilifelab.se
- Hans-Gustaf LjunggrenProfessor, Karolinska InstitutetVerified email at ki.se
- Aline PfefferleKarolinska InstituteVerified email at ki.se
- Béziat VivienInstitut ImagineVerified email at inserm.fr
- Kjetil TaskenProfessor of Medicine, Univ. of Oslo & Head, Institute of Cancer Research, Oslo University HospitalVerified email at medisin.uio.no
- Sandip PatelProfessorVerified email at ucl.ac.uk
- Herman NetskarUniversity of OsloVerified email at uio.no
- Melissa M. Berrien-ElliottSaint Louis University School of MedicineVerified email at health.slu.edu
- Ravi VijWashington UniversityVerified email at wustl.edu
- Jeff LeongWashington University School of MedicineVerified email at wusm.wustl.edu
- Todd A Fehniger MD/PhDProfessor of Medicine, Division of Oncology, Washington University School of Medicine in St. LouisVerified email at wustl.edu
- Maximillian RosarioJohns HopkinsVerified email at jhmi.edu
- Rizwan Romee, MDDana Farber Cancer Institute, Harvard Medical SchoolVerified email at dfci.harvard.edu
- Sten LinnarssonProfessor, Karolinska InstitutetVerified email at ki.se
- William LouchProfessor of Medicine, University of OsloVerified email at medisin.uio.no
Follow
Jode Goodridge
Other namesJodie Peter Goodridge
Fate Therapeutics
Verified email at fatetherapeutics.com